DK1608685T3 - VEGF antagonister til behandlingen af diabetes - Google Patents

VEGF antagonister til behandlingen af diabetes

Info

Publication number
DK1608685T3
DK1608685T3 DK04758372T DK04758372T DK1608685T3 DK 1608685 T3 DK1608685 T3 DK 1608685T3 DK 04758372 T DK04758372 T DK 04758372T DK 04758372 T DK04758372 T DK 04758372T DK 1608685 T3 DK1608685 T3 DK 1608685T3
Authority
DK
Denmark
Prior art keywords
vegf
diabetes
treatment
vegf antagonists
blocking
Prior art date
Application number
DK04758372T
Other languages
English (en)
Inventor
Mark W Sleeman
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK1608685T3 publication Critical patent/DK1608685T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04758372T 2003-03-28 2004-03-26 VEGF antagonister til behandlingen af diabetes DK1608685T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45879003P 2003-03-28 2003-03-28
PCT/US2004/009246 WO2004087206A2 (en) 2003-03-28 2004-03-26 Methods of treating diabetes by blocking vegf-mediated activity

Publications (1)

Publication Number Publication Date
DK1608685T3 true DK1608685T3 (da) 2007-06-11

Family

ID=33131825

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04758372T DK1608685T3 (da) 2003-03-28 2004-03-26 VEGF antagonister til behandlingen af diabetes

Country Status (17)

Country Link
US (1) US7052691B2 (da)
EP (1) EP1608685B1 (da)
JP (2) JP4730909B2 (da)
AT (1) ATE354592T1 (da)
AU (1) AU2004226417B2 (da)
BR (1) BRPI0408749B1 (da)
CA (1) CA2519787C (da)
CY (1) CY1106530T1 (da)
DE (1) DE602004004883T2 (da)
DK (1) DK1608685T3 (da)
ES (1) ES2278333T3 (da)
HK (1) HK1080092A1 (da)
MX (1) MXPA05008972A (da)
PL (1) PL1608685T3 (da)
PT (1) PT1608685E (da)
SI (1) SI1608685T1 (da)
WO (1) WO2004087206A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001241A (es) 2004-07-30 2007-07-11 Regeneron Pharma Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf.
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
ES2345596B1 (es) * 2009-03-26 2011-07-13 Fundacion Progreso Y Salud Composicion para la prevencion o el tratamiento de la diabetes mellitus.
US20100330098A1 (en) * 2009-06-29 2010-12-30 Kuo Calvin J Methods to regulate glucose metabolism
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AU2015208482B2 (en) 2014-01-25 2017-02-02 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases

Also Published As

Publication number Publication date
JP2006521397A (ja) 2006-09-21
EP1608685B1 (en) 2007-02-21
DE602004004883D1 (de) 2007-04-05
HK1080092A1 (en) 2006-04-21
DE602004004883T2 (de) 2007-11-15
CA2519787C (en) 2012-06-05
CA2519787A1 (en) 2004-10-14
AU2004226417B2 (en) 2009-01-22
BRPI0408749A (pt) 2006-03-28
US20040213787A1 (en) 2004-10-28
CY1106530T1 (el) 2012-01-25
MXPA05008972A (es) 2005-11-04
PL1608685T3 (pl) 2007-07-31
ATE354592T1 (de) 2007-03-15
WO2004087206A2 (en) 2004-10-14
JP4730909B2 (ja) 2011-07-20
US7052691B2 (en) 2006-05-30
ES2278333T3 (es) 2007-08-01
EP1608685A2 (en) 2005-12-28
PT1608685E (pt) 2007-05-31
SI1608685T1 (sl) 2007-08-31
WO2004087206A3 (en) 2004-12-16
BRPI0408749B1 (pt) 2016-10-04
AU2004226417A1 (en) 2004-10-14
JP2011037894A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
HK1080092A1 (en) Vegf antagonists for the treatment of diabetes
HK1105167A1 (en) Methods of treating type i diabetes by blocking vegf-mediated activity
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
EA200801118A1 (ru) Способ ингибирования flt3 киназы
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
DE60210093D1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
DK1836169T5 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
DK1781321T3 (da) Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
ATE428712T1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
DK1539200T3 (da) Fremgangsmåde til behandling af multipel sklerose
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
IS7970A (is) PDE4-hemlar til að meðhöndla eitlafrumuæxli
DE602005010258D1 (de) Behandlung von ballastwasser
EA200601220A1 (ru) Анти-trkc антитела-агонисты и способы их применения
WO2005070042A8 (en) Novel chemical compounds
BRPI0414724A (pt) combinação, composição farmacêutica, métodos para prevenir ou tratar aterosclerose em um animal de sangue quente e para prevenir eventos cardiovasculares em um animal de sangue quente, e, kit
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
DK2845594T3 (da) Anvendelse af dihydroimidazoloner til behandlingen af hunde.
DK1651774T3 (da) Anvendelse af polymorfier i humant OATP-C forbundet med en virkning på statinfarmakinetik i mennesker under statinterapi
ATE533769T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen